5 results
To validate the use of the Livv Mobiel ECG as a reliable office/bedside screening tool in primary care practice
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on theā¦
Purpose of this investigation is to establish which one of both treatments is most effective in resorption of the calcific deposit in the tendon and diminishing pain.
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).